ERYTECH to Present at the 2018 BIO CEO & Investor Conference
ERYTECH to Present at the 2018 BIO CEO & Investor Conference
Mr. Beyen will deliver ERYTECH's presentation detailing the Company's ERYCAPS platform and targeted treatment applications.
Details for the presentation are below:
Event: 2018 BIO CEO & Investor Conference
Date:
Time:
Mr. Beyen, CEO, will be available for one-on-one meetings on
About ERYTECH and eryaspase (GRASPA®): www.erytech.com
Founded in
The Company's lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multi-agent chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), but side effects limit treatment compliance, especially in adults and patients with weak performance status. With its improved safety profile, eryaspase aims to provide L-asparaginase to patients who cannot tolerate current non-encapsulated asparaginases.
ERYTECH is listed on the Nasdaq Global Select Market in
CONTACTS
ERYTECH Naomi Eichenbaum Director of Investor Relations |
The Ruth Group Lee Roth Investor relations Kirsten Thomas Media relations |
NewCap Julien Perez Investor relations Nicolas Merigeau Media relations |
+33 4 78 74 44 38 +1 917 312 5151 naomi.eichenbaum@erytech.com |
+1 646 536 7012 lroth@theruthgroup.com +1 508 280 6592 kthomas@theruthgroup.com |
+33 1 44 71 98 52 erytech@newcap.eu |